Skip to main content
. Author manuscript; available in PMC: 2013 Aug 5.
Published in final edited form as: Biochem Pharmacol. 2011 Aug 17;82(11):1562–1571. doi: 10.1016/j.bcp.2011.08.002

Table 3. Effect of selected compounds on viability of MDA-MB-231/R and MDA-MB-231/V cellsa.

Compound % Viability
MDA-MB-231/R MDA-MB-231/V
10 μM 5 μM 10 μM 5 μM
A-1 122 (9) NDb 101 ND
A-2 32 (4)c 35 (7) 37 (3)c 65 (19)
A-3 65 (4)c 82 (7) 86 (4)c 90 (2)
DA-1 56 (7)c 59 (6)d 108 (10)c 108 (8)d
UA-1 60 (8)c 68 (10)d 103 (7)c 98 (9)d
IA-1 68 (6)c 91 (10)d 97 (8)c 102 (6)d
HA-1 77 (21)c 88 (24) 108 (4)c 112 (7)
AZ-1 93 (9) 101 (15) 110 (3) 111 (7)
I-1 94 (10) 92 (10) 108 (5) 109 (14)
I-2 61 (10)c 65 (14) 93 (4)c 100 (9)
I-3 73 (13) 83 (10) 101 (5) 109 (13)
F-1 70 (3)c 94 (16) 97 (3)c 105 (6)
F-2 68 (4)c 88 (6) 88 (1)c 101 (3)
F-3 63 (16) 76 (13) 91 (4) 103 (6)
C-1 75 (4)c 112 (23) 92 (3)c 103 (4)
C-2 75 (14) 71 (2)d 84 (3) 90 (2)d
C-3 71 (12) 84 (4) 89 (1) 92 (6)
a

Percentage viability = (Average absorbance of wells with test compounds / Average absorbance of control wells with medium and 1% DMSO) × 100%. Values are mean (SD) of three independent determinations.

b

ND = Not detected.

c

Significant difference (p< 0.05) between % viability of R cells and V cells at 10μM by paired t test (2-sided).

d

Significant difference (p< 0.05) between % viability of R cells and V cells at 5μM by paired t test (2-sided).